[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05065060":3,"trial-entities:NCT05065060":87,"trial-summary:NCT05065060":90},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":26,"primary_purpose":27,"phases":28,"enrollment_info":29,"interventions":32,"primary_outcomes":35,"secondary_outcomes":40,"sex":41,"minimum_age":42,"maximum_age":27,"healthy_volunteers":43,"eligibility_criteria":44,"std_ages":52,"locations":55,"central_contacts":70,"overall_officials":74,"references":81,"see_also_links":86},"NCT05065060","PPMI-007","Parkinson Progression Marker Initiative Online (PPMI Online)","Parkinson's Progression Markers Initiative Online Study (PPMI Online)","RECRUITING","2041-12","2026-09","2026-09-08","2021-07-28","Michael J. Fox Foundation for Parkinson's Research","OTHER",false,"Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD.\n\nPPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.","PPMI is a broad program that is expanding the goals of the original PPMI study, and will include this PPMI Online protocol, as well the PPMI Clinical \\[NCT04477785\\], PPMI Remote, PPMI Digital protocols (with external regulatory oversight). All participants in PPMI may be asked to participate in one or all of these protocols and their enrollment in these studies may occur in varying order. PPMI participants may also be asked to participate in additional PPMI companion studies (as they are developed), which may only involve a subset of PPMI participants based on their cohort designation",[19],"Parkinson Disease",[21,22,23,24,25],"Parkinson","Neurodegenerative Disorder","Prodromal","At Risk","Participant Reported Outcomes","OBSERVATIONAL",null,[],{"count":30,"type":31},500000,"ESTIMATED",[33],{"type":14,"name":34,"description":34},"Observation",[36],{"measure":37,"description":38,"timeFrame":39},"Unified Parkinson's Disease Rating Scale Ib & II","Evaluates self-reported motor and nonmotor Parkinson's disease symptoms","Baseline to 240 months",[],"ALL","18 Years",true,{"inclusion":45,"exclusion":50,"raw_text":51},[46,47,48,47,49],"Parkinson Disease (PD) Participants:","Male or female age 18 years or older.","Has received a diagnosis of Parkinson's disease","Has not received a diagnosis of Parkinson's disease",[],"Inclusion Criteria:\n\n* Parkinson Disease (PD) Participants:\n\n  * Male or female age 18 years or older.\n  * Has received a diagnosis of Parkinson's disease\n\nParticipants without PD:\n\n* Male or female age 18 years or older.\n* Has not received a diagnosis of Parkinson's disease",[53,54],"ADULT","OLDER_ADULT",[56],{"facility":57,"status":8,"city":58,"state":59,"zip":60,"country":61,"contacts":62,"geoPoint":67},"UCSF Movement Disorders and Neuromodulation Center (MDNC)","San Francisco","California","94143","United States",[63],{"name":64,"role":65,"phone":66},"UCSF","CONTACT","877-525-7764",{"lat":68,"lon":69},37.77493,-122.41942,[71],{"name":72,"role":65,"phone":66,"email":73},"University of California, San Francisco","info@ppmionline.org",[75,78],{"name":76,"affiliation":72,"role":77},"Caroline Tanner, MD, PhD","PRINCIPAL_INVESTIGATOR",{"name":79,"affiliation":80,"role":77},"Kenneth L Marek, MD","Institute for Neurodegenerative Disorders",[82],{"pmid":83,"type":84,"citation":85},"41034300","DERIVED","Pierz KA, Aamodt W, Gochanour C, Kurth R, Brumm MC, Coffey CS, Heathers LE, Totten M, Doty RL, Marek K, Siderowf A; Parkinson's Progression Markers Initiative. Percentile scores for the revised University of Pennsylvania Smell Identification Test for 16,972 individuals 60 years of age and older. NPJ Parkinsons Dis. 2025 Oct 1;11(1):280. doi: 10.1038\u002Fs41531-025-01095-9.",[],{"nct_id":4,"conditions":88,"biomarkers":89},[19],[],{"nct_id":4,"found":43,"summary":91,"prompt_version":101},{"design":92,"status":93,"heading":94,"summary":95,"follow_up":96,"word_count":97,"commitments":98,"compensation":99,"drugs_mentioned":100},"This is an observational study, meaning researchers will collect information without giving any specific treatments. It aims to enroll up to 500,000 participants.","completed","PPMI Online: Understanding Parkinson's Disease","PPMI Online is an observational study that collects information from people with and without Parkinson's disease (PD). The goal is to better understand what puts someone at risk for PD and what factors predict its development. This study is part of a larger effort, the Parkinson Progression Marker Initiative, which aims to find markers that show how PD is changing over time. These markers could then be used in future studies to test new treatments that might slow down or stop the progression of PD. Researchers will be looking at how your Parkinson's symptoms change over a long period, up to 240 months (20 years). The study is currently recruiting, and they plan to enroll up to 500,000 participants. You can join if you are 18 years or older, with or without a diagnosis of Parkinson's disease.","Participants will be followed for up to 240 months (20 years) to assess changes in their Parkinson's symptoms.",137,"Not specified in the trial record.","Not stated in the trial record.",[34],"v2"]